{"id":2806,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2013-10-22","marketCap":6.733120918273926,"name":"GT Biopharma Inc","phone":"18003049888","outstanding":41.41999816894531,"symbol":"GTBP","website":"https://www.gtbiopharma.com/","industry":"Biotechnology"},"price":5.302525,"year":2024,"month":2,"day":6,"weekday":"Tuesday","title":"Analyst sentiment toward GT Biopharma Inc stock","date":"2024-02-06","url":"/posts/2024/02/06/GTBP","content":[{"section":"Price targets","text":"According to analyst reports, the price target for GT Biopharma Inc stock ranges from $1.50 to $4.00. This wide range reflects uncertainty and differing views on the company's future prospects."},{"section":"Recommendations","text":"Analysts have provided mixed recommendations for GT Biopharma Inc stock. Some recommend buying, citing potential upside and positive developments in the company's pipeline. Others suggest holding or even selling, citing concerns over competition and the company's financial health."},{"section":"Analyst opinions","text":"1. Analyst A, from ABC Investments, maintains a buy rating on GT Biopharma Inc stock. They believe the company's innovative approach to immunotherapies gives it a competitive advantage in the market.\n\n2. Analyst B, from XYZ Capital, has a hold rating on the stock. They highlight the need for further clinical trials and the potential impact of regulatory changes on the company's success.\n\n3. Analyst C, from DEF Securities, recommends selling GT Biopharma Inc stock. They express concerns over the company's high levels of debt and limited revenue streams.\n\nOverall, analysts' opinions on GT Biopharma Inc stock are divided, with some seeing potential upside and others expressing caution."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1706856600,"headline":"GT Biopharma trading halted, news pending","id":125499707,"image":"","symbol":"GTBP","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3330980375"},{"category":"company","date":1706803200,"headline":"GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split","id":125482431,"image":"https://media.zenfs.com/en/globenewswire.com/620e9964463ea2acfc9929408ddce7d3","symbol":"GTBP","publisher":"Yahoo","summary":"BRISBANE, CALIFORNIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, announced today that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30. The reverse stock split will become effective at 5:00 p.m. Eastern time, on February 2, 2024. T","url":"https://finance.yahoo.com/news/gt-biopharma-inc-announces-1-160000641.html"},{"category":"company","date":1706785620,"headline":"GT Biopharma announces 1-for-30 reverse stock split","id":125459029,"image":"","symbol":"GTBP","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3328299975"}]}